Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Neal Fischbach"'
Autor:
Julia Foldi, Andrea Silber, Emily Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michal Marczyk, Courtney Frederick, Trisha Burrello, Eiman Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L. Rimm, Lajos Pusztai
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract The goal of this Phase I/II trial is to assess the safety and efficacy of administering durvalumab concurrent with weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide (ddAC) neoadjuvant therapy for stages I–III triple-negativ
Externí odkaz:
https://doaj.org/article/a0cd120873bd4d7189d5d75f4bae0e84
Autor:
Julia Foldi, Andrea Silber, Emily Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michal Marczyk, Courtney Frederick, Trisha Burrello, Eiman Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L. Rimm, Lajos Pusztai
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/f95c42b14d2c4ab49587084764b1c998
Autor:
Robert Lindner, Catherine Sullivan, Onyinye Offor, Kimberly Lezon-Geyda, Kyle Halligan, Neal Fischbach, Mansi Shah, Veerle Bossuyt, Vincent Schulz, David P Tuck, Lyndsay N Harris
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e71915 (2013)
Triple negative breast cancer (TNBC) is characterized by high proliferation, poor differentiation and a poor prognosis due to high rates of recurrence. Despite lower overall incidence African American (AA) patients suffer from higher breast cancer mo
Externí odkaz:
https://doaj.org/article/4a94381861c3475db29ad350e4c60dd9
Autor:
Lajos Pusztai, David L. Rimm, Kim Blenman, Adam Blanchard, Tristen Park, Anees Chagpar, Anamika Katoch, Kerin Adelson, Justin Persico, Neal Fischbach, Emily Reisenbichler, Tao Qing, Andrea Silber, Adriana Kahn, Julia Foldi
Supplementary Table from Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a8cbe88cbebfb913c61351d386555bd
https://doi.org/10.1158/1078-0432.22486428.v1
https://doi.org/10.1158/1078-0432.22486428.v1
Autor:
Lajos Pusztai, David L. Rimm, Kim Blenman, Adam Blanchard, Tristen Park, Anees Chagpar, Anamika Katoch, Kerin Adelson, Justin Persico, Neal Fischbach, Emily Reisenbichler, Tao Qing, Andrea Silber, Adriana Kahn, Julia Foldi
Purpose:The incidence of triple-negative breast cancer (TNBC) is higher among Black or African American (AA) women, yet they are underrepresented in clinical trials. To evaluate safety and efficacy of durvalumab concurrent with neoadjuvant chemothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f28178b6ed9ae0ef095cd8736326b40
https://doi.org/10.1158/1078-0432.c.6532314
https://doi.org/10.1158/1078-0432.c.6532314
Autor:
Lajos Pusztai, David L. Rimm, Kim Blenman, Adam Blanchard, Tristen Park, Anees Chagpar, Anamika Katoch, Kerin Adelson, Justin Persico, Neal Fischbach, Emily Reisenbichler, Tao Qing, Andrea Silber, Adriana Kahn, Julia Foldi
Supplementary Figure from Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::426f0495c12e4bed2c6092b9984f6196
https://doi.org/10.1158/1078-0432.22486434
https://doi.org/10.1158/1078-0432.22486434
Autor:
Julia Foldi, Adriana Kahn, Andrea Silber, Tao Qing, Emily Reisenbichler, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Anees Chagpar, Tristen Park, Adam Blanchard, Kim Blenman, David L. Rimm, Lajos Pusztai
Publikováno v:
Clin Cancer Res
516 Background: The incidence of triple negative breast cancer (TNBC) is higher among Black or African American (AA) women, yet AA patients (pts) are underrepresented in clinical trials, exemplifying racial disparity in oncology. We conducted a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f600176c4dc64d90d5cc75523262d5b
https://europepmc.org/articles/PMC9444984/
https://europepmc.org/articles/PMC9444984/
Autor:
David Stokoe, Neal Fischbach, Wei-Fang Shen, Corey Largman, Christian Brandts, H. Jeffrey Lawrence, Ulka Vijapurkar
Publikováno v:
Molecular and Cellular Biology. 24:3827-3837
HOXA9 expression is a common feature of acute myeloid leukemia, and high-level expression is correlated with poor prognosis. Moreover, HOXA9 overexpression immortalizes murine marrow progenitors that are arrested at a promyelocytic stage of different
Autor:
Peter Gershkovich, Akosua Domfeh, G. Kenneth Haines, Mary Pronovost, Vinita Parkash, Neal Fischbach, Paul Cohen
Publikováno v:
American journal of clinical pathology. 142(1)
Objectives: Amended reports (AmRs) need to follow patients to treating physicians, to avoid erroneous management based on the original diagnosis. This study was undertaken to determine if AmRs followed the patient appropriately. Methods: AmRs with di
Publikováno v:
Leukemia. 19:1328-1330